Weda M - Search Results

1

On the formation of bromhexine impurity E and its chromatographic behaviour.

Venhuis BJ, Weda M, de Kaste D, Lamme EK. Venhuis BJ, et al. Among authors: weda m. Pharmeur Bio Sci Notes. 2012 Apr;2012:135-41. Pharmeur Bio Sci Notes. 2012. PMID: 23327897

2

Disintegration of sublingual tablets: proposal for a validated test method and acceptance criterion.

Weda M, van Riet-Nales DA, van Aalst P, de Kaste D, Lekkerkerker JF. Weda M, et al. Pharmeur Sci Notes. 2006 Dec;2006(2):41-4. Pharmeur Sci Notes. 2006. PMID: 17691213

3

Consistency of FMEA used in the validation of analytical procedures.

Oldenhof MT, van Leeuwen JF, Nauta MJ, de Kaste D, Odekerken-Rombouts YM, Vredenbregt MJ, Weda M, Barends DM. Oldenhof MT, et al. Among authors: weda m. J Pharm Biomed Anal. 2011 Feb 20;54(3):592-5. doi: 10.1016/j.jpba.2010.09.024. Epub 2010 Oct 20. J Pharm Biomed Anal. 2011. PMID: 20970277

4

Drug output of unvented jet nebulizers as a function of time.

Diederik H, Le Brun PP, Frijlink HW, Vitányi PM, Weda M, Barends DM. Diederik H, et al. Among authors: weda m. Int J Pharm. 2003 May 12;257(1-2):33-9. doi: 10.1016/s0378-5173(03)00109-1. Int J Pharm. 2003. PMID: 12711159

5

The therapeutic index of locally acting inhaled drugs as a function of their fine particle mass and particle size distribution: a literature review.

Weda M, Zanen P, de Boer AH, Barends DM, Frijlink HW. Weda M, et al. Curr Drug Deliv. 2008 Apr;5(2):142-7. doi: 10.2174/156720108783954897. Curr Drug Deliv. 2008. PMID: 18393817 Review.

6

Equivalence testing and equivalence limits of metered-dose inhalers and dry powder inhalers measured by in vitro impaction.

Weda M, Geuns ER, Vermeer RC, Buiten NR, Hendriks-de Jong K, Bult A, Zanen P, Barends DM. Weda M, et al. Eur J Pharm Biopharm. 2000 May;49(3):295-302. doi: 10.1016/s0939-6411(00)00064-3. Eur J Pharm Biopharm. 2000. PMID: 10799822

7

An investigation into the predictive value of cascade impactor results for side effects of inhaled salbutamol.

Weda M, Zanen P, de Boer AH, Barends DM, Frijlink HW. Weda M, et al. Int J Pharm. 2004 Dec 9;287(1-2):79-87. doi: 10.1016/j.ijpharm.2004.08.017. Int J Pharm. 2004. PMID: 15541915 Clinical Trial.

8

Equivalence testing of salbutamol dry powder inhalers: in vitro impaction results versus in vivo efficacy.

Weda M, Zanen P, de Boer AH, Gjaltema D, Ajaoud A, Barends DM, Frijlink HW. Weda M, et al. Int J Pharm. 2002 Dec 5;249(1-2):247-55. doi: 10.1016/s0378-5173(02)00533-1. Int J Pharm. 2002. PMID: 12433452 Clinical Trial.

9

Potential association between the recent increase in campylobacteriosis incidence in the Netherlands and proton-pump inhibitor use - an ecological study.

Bouwknegt M, van Pelt W, Kubbinga ME, Weda M, Havelaar AH. Bouwknegt M, et al. Among authors: weda m. Euro Surveill. 2014 Aug 14;19(32):20873. doi: 10.2807/1560-7917.es2014.19.32.20873. Euro Surveill. 2014. PMID: 25139075 Free article.

10

Metal versus plastic spacers: an in vitro and in vivo comparison.

Janssen R, Weda M, Ekkelenkamp MB, Lammers JW, Zanen P. Janssen R, et al. Among authors: weda m. Int J Pharm. 2002 Oct 1;245(1-2):93-8. doi: 10.1016/s0378-5173(02)00330-7. Int J Pharm. 2002. PMID: 12270246 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18 results

Search Page

Filters